Infrareal to Take Over Takeda’s Gene and Cell Therapy Site in Orth, Austria
Infrareal Holding plans to take over Takeda’s pharma and biotech site specialising in gene and cell therapies in Orth, Lower Austria, 30km east of Vienna. The two companies signed a corresponding transfer agreement. Takeda will transfer the 24-hectare site, including buildings, infrastructure, and some pharmaceutical production facilities, to Infrareal. The agreement is subject to customary legal and regulatory pre-closing conditions, including merger control approval in Austria.
Dr Martin Egger, CEO and spokesperson for the management of Infrareal, explained:
“Over the last 40 years and more, Orth an der Donau has developed into a centre of excellence for the pharmaceutical and life science industries, focusing on gene and cell therapy and biologics. Our expertise will help us to further expand the site, and we are hoping to attract more companies from these industries.”
Matt Payne, Head of Global Biologics Operating Unit at Takeda, said:
“With Infrareal, we have found an experienced pharmaceutical and life science site operator who plans to further develop the Orth site and who can build on the existing knowledge. We are pleased to have found a buyer who shares our ambitions for sustainable processes and site decarbonization.”
Infrareal will be responsible for all services at the site via its subsidiary PharmaparkOrth Management GmbH. These include services such as media supply, recycling, other infrastructure and engineering services as well as site development.
Dr Martin Egger added:
“One key component of Infrareal’s philosophy is that we, as the owner and operator, continue to develop our sites. This also includes marketing any free space, promoting the decarbonisation of our locations and contributing our strengths in pharmaceutical logistics and on-site technology.”
Infrareal boasts many years of experience in the development and operations of pharma sites. Marburg is not the only location where Infrareal and its subsidiaries offer wide-ranging industry solutions in the fields of real estate, technology and logistics. In Orth, 34 employees in the areas of infrastructure and engineering will transition from Takeda to PharmaparkOrth Management GmbH. Their local expertise will be a great advantage when running and further developing the site.
With the planned takeover, Infrareal is realising its published strategy of becoming one of the leading operators of pharmaceutical and biotech locations in German-speaking countries. The planned acquisition of the site in Orth also forms part of this strategy. In addition to the existing buildings and facilities, the available free space will also be developed and marketed to generate further growth. Infrareal will harvest synergies and innovative infrastructure solutions to ensure cost savings and transparent pricing models, thereby creating long-term prospects for the partner companies on site.
Referring to the successful operations of Behringwerke Marburg and Pharmapark Jena, Dr Martin Egger explained:
“Together with our owners Swiss Life Asset Managers and Gelsenwasser AG, we will be pursuing a long-term growth strategy for our locations. This creates security for our customers and employees while forming the basis for sustainable development. Orth offers an ideal environment for biopharmaceutical companies.”
As a service company with over 800 employees, Infrareal cares particularly about a holistic and sustainable people strategy and shared values. These include transparent communication, accountability, cooperation across different departments, as well as a clear commitment to sustainability goals.
Peter Michael Weimar, COO of Infrareal and Managing Director of PharmaparkOrth Management, emphasised:
“We are excited about the new addition to the Infrareal Group and feel certain of the potential of the pharmaceutical and biotech location in Orth.”
Orth is an attractive location for international companies in the biopharmaceutical industry because of the facilities and infrastructure available at the Pharmapark, its highly qualified employees and its proximity to Vienna International Airport and the Austrian capital. In addition to Takeda, another big pharmaceutical company is also located at the Orth site.
About Infrareal
Infrareal Holding is a management holding company and one of the leading groups of site operating companies specialising in the operation and development of industrial and business parks, with a focus on pharmaceuticals and life science. The company is owned by Swiss Life Asset Managers and Gelsenwasser AG and pursues a one-company approach, offering our customers an extensive range of services in the areas of professional management, infrastructure, technology and logistics from a single source. Via its subsidiary Pharmaserv, Infrareal has been providing extensive real estate, technology and logistics services for more than 25 years.
In the technology area, Pharmaserv offers technical services across Germany which are specifically tailored to the requirements of the pharmaceutical industry, including project management, facility construction, maintenance and repairs. In addition to its location in Marburg, Pharmaserv also has branches in Frankfurt, Cologne and Jena.
Via Pharmaserv Logistics, the Infrareal Group also offers comprehensive logistics solutions, including raw material storage, finished pharmaceuticals distribution and global shipment by truck, air and sea freight, using its sites in Marburg, Groß-Gerau and Lützellinden.
With its many years of experience and 800 employees, Infrareal successfully operates pharmaceutical and biotechnology parks in Marburg and Jena, which together employ over 7,000 people. The company’s philosophy consists of transparent pricing models, customized offers and employee development. As the owner and operator of the sites, Infrareal makes long-term investments, while continuing to develop and strive for high customer satisfaction.
Latest Projects
- Infrareal to Take Over Takeda’s Gene and Cell Therapy Site in Orth, Austria
Infrareal Holding plans to take over Takeda’s pharma and biotech site specialising in gene and cell therapies in Orth, Lower - J&J to Invest Over $2 Billion in Biologics Manufacturing Facility, North Carolina
Johnson & Johnson has announced a significant investment exceeding $2 billion to establish a cutting-edge biologics manufacturing facility in Wilson, - Arctoris Acquires Eli Lilly’s ‘Life Science Studio’ Drug Discovery Automation Lab
Through the strategic acquisition of Eli Lilly’s San Diego ‘Life Science Studio’, Arctoris’ has doubled the size of its existing - Eli Lilly to Expand API’s Plant Boosting Diabetes and Obesity Drugs Manufacturing in Indiana, USA
Eli Lilly and Company has announced that it has more than doubled its investment in its Lebanon, Indiana, USA manufacturing - AstraZeneca to Build $1.5B ADCs Manufacturing Facility in Singapore
In a strategic move to bolster its global supply of antibody-drug conjugates (ADCs), AstraZeneca has announced the development of a - Animal Immunology and Preclinical Research Facility, Behring Campus Eystrup, Germany
The Behring Campus Eystrup is a cutting-edge research facility specialising in animal immunology, antibody development, and preclinical research. Located at
